RxDoctor Payments Data

Matthew Brumbaugh, MD

Internal Medicine · Attleboro, MANPI 1346478534

Payments from drug & device makers

$529in general payments, 2019–2025

Across 29 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$108
  • Boston Scientific$100
  • Amarin Pharma, Inc.$41
  • Novo Nordisk$38
  • Pfizer$35
  • AstraZeneca$30
  • plus $176 from 11 others

What the payments were for

  • Grants$10019%
  • Food & beverage$42981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$33,255
Medicare patients
124
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$45,748
EliquisApixaban22$23,575
XareltoRivaroxaban17$14,878
OxycontinOxycodone Hcl13$10,987
Breo ElliptaFluticasone/Vilanterol26$10,922
OzempicSemaglutide11$9,852
SynthroidLevothyroxine Sodium55$3,795
Rosuvastatin Calcium124$2,437
Candesartan Cilexetil14$2,020
Atorvastatin Calcium218$1,931
Ezetimibe20$1,080
Potassium Chloride20$1,026
Levothyroxine Sodium114$1,000
Cephalexin34$814
Chlorthalidone23$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$23,57522 claims
Johnson & JohnsonXarelto$16$14,87817 claims
GSKBreo Ellipta$17$10,92226 claims
Novo NordiskOzempic$38$9,85211 claims
AbbVieSynthroid$13$3,79555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →